Insmed (INSM)

Executive Summary

Insmed is a global biopharmaceutical company focused on developing therapies for serious and rare diseases, with a strong pipeline in respiratory and pulmonary hypertension indications. The company's lead product, Arikayce (amikacin liposome inhalation suspension), is approved for refractory NTM lung disease and continues to generate revenue. Insmed's pipeline includes brensocatib, an oral DPP-1 inhibitor in Phase 3 for bronchiectasis, and treprostinil palmitil, an inhaled prodrug for pulmonary arterial hypertension (PAH) currently in Phase 2/3 trials. The company also has early-stage assets, including rhIGF-I/rhIGFBP-3 for growth hormone insensitivity syndrome. With a market cap of ~$20 billion, Insmed is well-positioned for growth driven by upcoming data readouts and potential label expansions. Key risks include competition in PAH and uncertainty around brensocatib's regulatory path.

Upcoming Catalysts (preview)

• H2 2025Brensocatib Phase 3 Aspen trial results in bronchiectasis70% success
• Q4 2026Treprostinil palmitil Phase 2/3 data in PAH55% success
• H1 2026Potential FDA decision on Arikayce label expansion for pediatric NTM60% success